1. Home
  2. AXTA vs NUVL Comparison

AXTA vs NUVL Comparison

Compare AXTA & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axalta Coating Systems Ltd.

AXTA

Axalta Coating Systems Ltd.

HOLD

Current Price

$28.11

Market Cap

5.9B

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$98.91

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXTA
NUVL
Founded
1910
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Paints/Coatings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
8.1B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AXTA
NUVL
Price
$28.11
$98.91
Analyst Decision
Buy
Strong Buy
Analyst Count
14
15
Target Price
$35.92
$135.33
AVG Volume (30 Days)
2.4M
437.9K
Earning Date
05-12-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.74
N/A
Revenue
$5,117,000,000.00
N/A
Revenue This Year
$3.56
N/A
Revenue Next Year
$2.93
$1,064.25
P/E Ratio
$16.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.28
$55.54
52 Week High
$35.72
$113.02

Technical Indicators

Market Signals
Indicator
AXTA
NUVL
Relative Strength Index (RSI) 25.03 44.15
Support Level $27.43 $98.37
Resistance Level $29.47 $107.13
Average True Range (ATR) 0.92 3.66
MACD -0.42 -0.27
Stochastic Oscillator 10.82 29.17

Price Performance

Historical Comparison
AXTA
NUVL

About AXTA Axalta Coating Systems Ltd.

Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: